Member Info for lambo222

Ah it’s all good fun, but the facts remain that investors buying today at these low levels could easily 3-4 times their money over the next few weeks, I do t think many people realise the potential of Lupozor for Lupus, if the phase 3 trial is approved and ultimately successful we are talking about potentially the best safest treatment for Lupus globally which is a $10bn market, Art Deas himself stated that he sees Lupozor as Avions number 1 drug in the future, US buyers will be all over this in the future as they cannot buy Avion given it’s a private company so IMM is their only route to get exposure to Lupozor, biggest month in the companies history coming up, you either sit it out or take the chance but you have to be in it to win it

In conjunction with these objectives, the Company has been continuing to manage its cost base which demonstrates a cash runway through the end of 2023 and into the first half of 2024.

Tuesdays FDA meeting for CIDP could really ignite the fire here and get momentum building ahead of the Lupozor phase 3 FDA approval meeting on 7th June, as we know with IMM once momentum builds it really does motor and we have two company making catalysts coming up, one of which unlocks $25m funding from our US partner Avion in a $10 billion Lupus market that currently only has two treatments with severe side effects, Lupozor is safe and little to no side effects the potential on offer here is mind boggling imo potentially the next world leader in Lupus treatment and the Mcap is £10m… huge rewards on offer for buyers at this level

Watch this rocket next week, i think you miss the point Nolupus people are invested here to make money, been right and acting smart doesn’t make you any money unfortunately, knowing when to buy and sell does…. Two major catalysts due on next week 16th May, one 3 weeks later on 7th June… if FDA are positive on both what do you think the price will be? higher than 2.6p that’s for sure 10p entirely possible you pay your money you take your chance, but over the next few weeks this is going to light up make no mistake

I know this share like the back of my hand, a day like today is perfect for picking up some cheap shares ahead of two major inflection points, 16th May FDA meeting for CIDP, 7th June FDA meeting to approve Lupozor phase 3, we get both of these then what is a company worth that has two phase 2/3 trials going in multi billion dollar potential markets, with Lupozor funded for $25m by Avion….. 10p and well north of 10p would be my guess especially with the Lupus market in desperate need of new drugs, a nice licensing deal for CIDP and an upfront cash payment to IMM is what they have planned and if that comes off there won’t be the need for any more dilution, even a small £5m upfront licensing payment would cover IMM for 2 years! Lots to look forward to over the next month, 2 huge company making catalysts, appproval on Tuesday and we will be building towards 5p ahead of the main event on 7th June for Lupozor, never in IMM history has it not moved up significantly into an FDA decision date, this time is no different apart from the fact the share price is beaten down, positive news and this multibags a good few times over

FDA meeting on Tuesday 16th May for CIDP…. Positive news here sees IMM back above 3.5p in the blink of an eye, $3 billion market, Orphan drug designation to be submitted, then we push forward to the main event in 7th June for Lupozor phase 3 approval, both these get approved and we are well over 10p by mid June imo

“In conjunction with these objectives, the Company has been continuing to manage its cost base which demonstrates a cash runway through the end of 2023 and into the first half of 2024.” The most important month in IMM history coming up with two pivotal FDA meetings one of which for Lupus unlocks $25m of funding from Avion if approved… investors will be queuing up if we get FDA approval on 7th June with a price in double digits Imo

Thank you sellers…. Savvy buyers loading in the dip, funding won’t be an issue if they get FDA approval on 7th June, also the fact the bod say they are funded until early 2024…. They can’t issue an rns stating that if they are not… and the results are up to 31st December 2022, since then we have had Lanstead payments, Orion payment, next to no admin costs etc. more shares bought than sold today if that doesn’t tell you where this is heading I don’t know what does

What do you mean? Lanstead is the funder for IMM they sell their holding down to zero gradually over the course of the agreement, surely you know this by now they have been using Lanstead for years

One of the most badly managed companies on aim imo and that’s saying something, no funding, no news, no updates just oh actually the death spiral funding we had in place well yeah that’s cancelled we will try get something else in place if we can lol be lucky to get a placing away at 2p now

I imagine those who bought at sub 2p over the last few months May take a few off the table before the 7th June meeting, makes sense to lock in 50% profit just in case the FDA play hard ball yet again, question is do IMM do a placing before the meeting date they they have done twice before or do they risk it all on the FDA decision…

It’s all about the FDA decision on 7th June, it will
Take balls of steal to hold for the result given it’s a whole new protocol and phase2/3 adaptive trial FDA may want to see the dosing data first before allowing phase 3, as ever with IMM the swings are wild you can be up 50% one minute and down 50% the next…nature of the beast

Issue is it will take even longer now it’s a phase 2/3 adaptive trail your looking at 3 years plus for top line results, FDA will eventually approve only concern I have is will they come back and say they want a separate phase 2 then they look at the phase 2 data before a phase 3 can start, again more delays that’s the risk as I said 1.5p or 5p is the straight gamble imo

Well still no news on drilling and no news on finance either… mcap ridiculously high given the risks of nothing happening this year

The price hasn’t moved there have been 22 small trades… sure was a mega pump and dump haha long as they don’t do a placing before the FDA decision in June it should hover around 2.5-3p, if FDA say no to phase 2/3 adaptive and want a full phase 2 then review I would suggest another year delay so it’s either 1.5p one 5p plus imo binary outcome

Good apart from Tim already signposting FDA delays to the meeting dates which isn’t great, hopefully the price can hold this level of around 2.8p and Lanstead don’t dump any until the meeting results

Unfortunately it looks like it has been mostly spent

Neither it’s just clear that if the CLN didn’t want shares at 2.5p then why should the humble pi

Amazed people do not see the significance of the CLN pulling out, do people really believe that the US company who had every legal right to convert $2m at 2.5p into Jay shares decided not to just people Jay said please sir let’s cancel this deal we have a better one lined up and don’t want you to convert at 2.5p as we think we can raise money higher. They would have turned around and said ok well once you raise money higher, we will convert our 2.5p shares, sell them and be on our merry way… the CLN has taken a look at the pitiful volumes, the high chance of no Disko drilling, and thought hmm this looks like a dead duck we can’t make much money at 2.5p here as the volume of buyers just simply doesn’t exist. Drill season now starting up in Greenland yet Jay has no drill contractor or contract, no money to pay them and no new from Kolbold… yet the bod pocket eye watering salaries and hardly own any shares, we have been had on this one unfortunately

Ok so if the CLN holder actually thought JAY had value above 2.5p then why didn’t they convert the $2m into JAY shares? They have had 2 months to do so…. Yet chose not to, sounds better if JAY said they cancelled it just like a football manager gets sacked but they state mutual consent. Total silence on Disko, no funding for Kang drill campaign, and Dundas the less said about that the better, so what can JAY offer now newsflow wise apart from a placing